Your browser doesn't support javascript.
loading
Psychometric Properties of Clinical Indicators for Identification and Management of Advanced Parkinson's Disease: Real-World Evidence From G7 Countries.
Antonini, Angelo; Pahwa, Rajesh; Odin, Per; Henriksen, Tove; Soileau, Michael J; Rodriguez-Cruz, Ramon; Isaacson, Stuart H; Merola, Aristide; Lindvall, Susanna; Domingos, Josefa; Alobaidi, Ali; Jalundhwala, Yash J; Kandukuri, Prasanna L; Parra, Juan Carlos; Kukreja, Pavnit K; Onuk, Koray; Bergmann, Lars; Pike, James; Ray Chaudhuri, K.
Afiliação
  • Antonini A; Parkinson and Movement Disorders Unit, Study Centre for Neurodegeneration, Department of Neuroscience, University of Padova, Padova, Italy.
  • Pahwa R; Medical Center, University of Kansas, Kansas, KS, USA.
  • Odin P; University of Lund, Lund, Sweden.
  • Henriksen T; Movement Disorder Clinic, University Hospital of Bispebjerg, Copenhagen, Denmark.
  • Soileau MJ; Texas Movement Disorder Specialists, Georgetown, TX, USA.
  • Rodriguez-Cruz R; Synaptic Precision, Inc, Orlando, FL, USA.
  • Isaacson SH; Parkinson's Disease and Movement Disorders Center, Boca Raton, FL, USA.
  • Merola A; Madden Center for Parkinson Disease and Other Movement Disorders, Department of Neurology, The Ohio State University Wexner Medical Center, Columbus, OH, USA.
  • Lindvall S; European Parkinson's Disease Association, Sevenoaks, UK.
  • Domingos J; European Parkinson's Disease Association, Sevenoaks, UK.
  • Alobaidi A; Grupo de Patologia Médica, Nutrição e Exercício Clínico (PaMNEC) do CiiEM, Almada, Portugal.
  • Jalundhwala YJ; AbbVie Inc., North Chicago, IL, USA.
  • Kandukuri PL; University of Illinois at Chicago, Chicago, IL, USA.
  • Parra JC; AbbVie Inc., North Chicago, IL, USA.
  • Kukreja PK; AbbVie Inc., North Chicago, IL, USA.
  • Onuk K; AbbVie Inc., North Chicago, IL, USA.
  • Bergmann L; AbbVie Inc., North Chicago, IL, USA.
  • Pike J; AbbVie Inc., North Chicago, IL, USA.
  • Ray Chaudhuri K; AbbVie Inc., North Chicago, IL, USA.
Neurol Ther ; 11(1): 303-318, 2022 Mar.
Article em En | MEDLINE | ID: mdl-35015215
ABSTRACT

INTRODUCTION:

Standardized and validated criteria to define advanced Parkinson's disease (PD) or identify patient eligibility for device-aided therapy are needed. This study assessed the psychometric properties of clinical indicators of advanced PD and eligibility for device-aided therapy in a large population.

METHODS:

This retrospective analysis of the Adelphi Parkinson's Disease Specific Programme collected data from device-aided therapy-naïve people with PD in G7 countries. We assessed the presence of 15 clinical indicators of advancing PD and seven indicators of eligibility for device-aided therapy in patients classified with advanced PD or as eligible for device-aided therapy by the treating physician. Accuracy was assessed using area under the curve (AUC) and multivariable logistic regression models. Construct validity was examined via known-group comparisons of disease severity and burden among patients with and without each clinical indicator.

RESULTS:

Of 4714 PD patients, 14.9% were classified with advanced PD and 17.5% as eligible for device-aided therapy by physician judgment. The presence of each clinical indicator was 1.9- to 7.3-fold more likely in patients classified with advanced PD. Similarly, the presence of device-aided therapy eligibility indicators was 1.8- to 5.5-fold more likely in patients considered eligible for device-aided therapy. All indicators demonstrated high clinical screening accuracy for identifying advanced PD (AUC range 0.84-0.89) and patients eligible for device-aided therapy (AUC range 0.73-0.80). The Unified Parkinson's Disease Rating Scale (UPDRS) score, cognitive function, quality of life, and caregiver burden were significantly worse in indicator-positive patients.

CONCLUSION:

Specific clinical indicators of advanced PD and eligibility for device-aided therapy demonstrated excellent psychometric properties in a large sample, and thus may provide an objective and reliable approach for patient identification and treatment optimization.
Advanced Parkinson's disease (PD) refers to the stage of disease when motor complications are difficult to manage with standard therapy. Patients reaching this stage of the disease may benefit from a treatment change from pills to the so-called device-aided therapies. However, there is currently no unanimous definition of advanced PD, which makes it challenging to identify suitable candidates for device-aided therapies. There is urgent need to define specific features (or 'clinical indicators') to support healthcare professionals and patients in the identification of advanced PD as well as to define suitability for device-aided therapy. This study aimed to assess the accuracy of 15 clinical indicators and seven device-aided therapy eligibility criteria using information from a large database of 4714 patients in G7 countries. Physicians classified 14.9% of patients as having advanced PD and 17.5% were judged to be eligible for device-aided therapy. Each clinical indicator or device-aided therapy eligibility indicator was detected more frequently in patients classified as having advanced PD and in patients considered eligible for device-aided therapy, respectively. All indicators had high accuracy for identifying advanced PD and device-aided therapy-eligibility. These previously identified clinical indicators of advanced PD and device-aided therapy eligibility may provide an objective and reliable approach for patient screening and treatment optimization.
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Diagnostic_studies / Prognostic_studies Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Diagnostic_studies / Prognostic_studies Idioma: En Ano de publicação: 2022 Tipo de documento: Article